| Literature DB >> 25870628 |
Ahmad Sharafi1, Hamid Reza Pour Hosseini1, Arash Jalali1, Mojtaba Salarifar1, Ebrahim Nematipour1, Mohsen Shojanasab1, Hassan Aghajani1, Alireza Amirzadegan1, Younes Nozari1, Mohamad Alidoosti1, Alimohammad Haji Zeinali1, Seyed Ebrahim Kassaian1.
Abstract
BACKGROUND: Controversy persists over the potential benefits/harms of opium consumption in coronary heart disease. This study investigated the association between 12 months' major adverse cardiac events (MACE) and pre-procedural opium consumption among patients undergoing percutaneous coronary intervention (PCI).Entities:
Keywords: Major adverse cardiac event; Opium; Percutaneous coronary intervention
Year: 2014 PMID: 25870628 PMCID: PMC4393833
Source DB: PubMed Journal: J Tehran Heart Cent ISSN: 1735-5370
Figure 1.Study profile, describing the patients’ recruitment and allocation steps POBA, Plain old balloon angioplasty
Figure 2.The Kaplan Meier survival curves of major adverse cardiac events in the two groups
Characteristics of the patients
| Opium consumption | P value | ||
|---|---|---|---|
| Yes (n=350) | No (n=1195) | ||
| Risk Factors | |||
| FH | 54/347 (15.6) | 184/1189 (15.5) | 0.969 |
| HLP | 195 (55.7) | 681 (57) | 0.672 |
| Cigarette smoking | < 0.001 | ||
| No | 60 (17.1) | 628 (52.6) | |
| Former | 74 (21.1) | 224 (18.7) | |
| Current | 216 (61.7) | 343 (28.7) | |
| HTN | 134 (38.3) | 518 (43.3) | 0.092 |
| DM | 69 (19.7) | 297 (24.9) | 0.047 |
| History of MI | 204/348 (58.6) | 656/1187 (55.3) | 0.267 |
| History of PCI | 30 (8.6) | 118 (9.9) | 0.466 |
| History of CABG | 21 (6) | 73 (6.1) | 0.94 |
| Stent Type | 0.152 | ||
| BMS | 131 (37.4) | 411 (34.4) | |
| DES | 179 (51.1) | 676 (56.6) | |
| Mixed | 40 (11.4) | 108 (9) | |
| Procedural numbers | 0.347 | ||
| 1 | 264 (75.4) | 868 (72.6) | |
| 2 | 66 (18.9) | 270 (22.6) | |
| 3 | 16 (4.6) | 50 (4.2) | |
| 4 | 4 (1.1) | 7 (0.6) | |
| Age (y) | 55.7 (9.2) | 58.4 (10.8) | < 0.001 |
| BMI (Kg/m2) | 26.8 (4.1) | 27.2 (4) | 0.095 |
| Abdominal circumference (cm) | 98.7 (10.4) | 99.9 (9.8) | 0.052 |
| EF (%) | 50.1 (9.4) | 49.5 (9.6) | 0.269 |
| RVD mean (mm) | 3.33 (0.49) | 3.31 (0.48) | 0.534 |
| Lesion length (mm) | 21.12 (9.11) | 20.88 (9.1) | 0.674 |
| Type C | 207 (59.1) | 689 (57.7) | 0.620 |
| Ostial | 36 (10.3) | 134 (11.2) | 0.626 |
| LAD | 175 (50) | 723 (60.5) | < 0.001 |
| SVG | 9 (2.6) | 23 (1.9) | 0.455 |
| Stent diameter (mm) | 3.23 (0.45) | 3.21 (0.44) | 0.609 |
| Stent length (mm) | 22.7 (7.23) | 22.59 (6.96) | 0.794 |
Data are presented as n (%) or proportion (%)
FH, Family history; HLP, Hyperlipidemia; MI, Myocardial infarction; HTN, Hypertension; DM, Diabetes mellitus; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass graft; BMI, Body mass index; EF, Ejection fraction; RVD, Reference vessel diameter; LAD, Left anterior descending; SVG, Saphenous vein graft
Comparison of clinical 12 months’ outcomes between the opium consumption and control groups
| Opium consumption | Log-rank test p value | ||
|---|---|---|---|
| Yes (n=350) | No (n=1195) | ||
| MACE | 11 (3.1) | 53 (4.4) | 0.286 |
| TVR | 9 (2.6) | 27 (2.3) | 0.75 |
| TLR | 3 (0.9) | 11 (0.9) | 0.909 |
| CABG | 5 (1.4) | 11 (0.9) | 0.421 |
| Non-fatal MI | 3 (0.9) | 14 (1.2) | 0.617 |
| All-cause mortality | 2 (0.6) | 20 (1.7) | 0.144 |
| Cardiac death | 2 (0.6) | 14 (1.2) | 0.337 |
MACE, Major adverse cardiac event; TVR, Target vessel revascularization; TLR, Target lesion revascularization; CABG, Coronary artery bypass graft; MI, Myocardial infarction